文献速递肿瘤 PET/CT骨显像与常规 SPECT

前列腺癌患者中[68Ga]-Ga-PSMA-11与[18F]-F-PSMA-1007的个体内比较:单中心回顾性分析

Intraindividual comparison of [68 Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis.
PubMed 文献 · EJNMMI Res · 2021-10-19

该单中心回顾性分析对46例前列腺癌患者进行个体内比较,评估[68Ga]-Ga-PSMA-11与[18F]-F-PSMA-1007在恶性病灶、miTNM分期及疑似非特异性病灶上的差异。结果显示两种示踪剂在miTNM分期上的一致性为80.4%,SUVmax无显著差异,但[18F]-F-PSMA-1007在淋巴结、骨骼和神经节的疑似非特异性摄取显著更多。结论认为两种示踪剂在分期上可广泛互换,选择可依据当地可及性,但需注意[18F]-F-PSMA-1007更易出现非特异性骨 findings。

要点

  • 两种示踪剂miTNM分期一致率为80.4%,仅19.6%患者分期不同。
  • 局部、淋巴结及骨转移灶SUVmax在两种示踪剂间无显著差异。
  • [18F]-F-PSMA-1007在淋巴结、骨骼和神经节的疑似非特异性摄取显著更多。

核心结论

  • 两种示踪剂在miTNM分期上可广泛互换,无一种示踪剂明显优于另一种。
  • 两种示踪剂的差异在疑似非特异性病灶中远比恶性病灶常见。
  • 常规进行双示踪剂研究未显示优越性。
  • 选择PSMA示踪剂可依据当地可及性,但需注意[18F]-F-PSMA-1007更易出现非特异性骨 findings。

研究设计与样本

  • 回顾性单中心分析46例前列腺癌患者(中位年龄71岁),患者平均在12±8.0天内连续接受[68Ga]-Ga-PSMA-11和[18F]-F-PSMA-1007 PET/CT或PET/MRI。
  • 由两名对另一种示踪剂结果不知情的核医学医师进行miTNM分期,并经与两名放射科医师的学科内和学科间共识后分析差异。

主要发现

  • 9/46例(19.6%)患者miTNM分期不同,其中miT分期不同5例(10.9%),miN分期不同3例(6.5%),miM分期不同仅1例(在[18F]-F-PSMA-1007 PET中升级)。
  • 37例(80.4%)患者miTNM分期一致。
  • [18F]-F-PSMA-1007与[68Ga]-Ga-PSMA-11的SUVmax在局部(31.5 vs. 32.7;p=0.658)、淋巴结转移(28.9 vs. 24.9;p=0.30)和骨转移(22.9 vs. 27.6;p=0.286)中均无显著差异。
  • [18F]-F-PSMA-1007 PET中更多患者出现疑似非特异性摄取:淋巴结(52.2% vs. 28.3%;p<0.001)、骨骼(71.7% vs. 23.9%;p<0.001)和神经节(71.7% vs. 43.5%;p<0.001)。
  • 可能非特异性、仅[18F]-F-PSMA-1007阳性的病灶主要位于肋骨(58.7%)、腋窝淋巴结(39.1%)和颈部神经节(28.3%)。

临床怎么用

  • 两种示踪剂在miTNM分期上可广泛互换,选择可依据当地可及性。
  • 使用[18F]-F-PSMA-1007时需注意其更易出现非特异性骨、淋巴结和神经节摄取,避免误判。
  • 常规双示踪剂研究未显示优越性,不推荐作为常规。

局限性

  • 回顾性单中心分析,样本量有限(46例)。
  • 两种示踪剂PET/CT或PET/MRI检查间隔平均12±8.0天,可能影响病灶比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The analysis aimed to compare the radiotracers [68Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 intraindividually in terms of malignant lesions, mi(molecular-imaging)TNM staging and presumable unspecific lesions retrospectively as used in routine clinical practice. METHODS: A retrospective analysis of 46 prostate cancer patients (median age: 71 years) who underwent consecutive [68Ga]-Ga-PSMA-11- and [18F]-F-PSMA-1007-PET/CT or PET/MRI within a mean of 12 ± 8.0 days was performed. MiTNM staging was performed in both studies by two nuclear medicine physicians who were blinded to the results of the other tracer. After intradisciplinary and interdisciplinary consensus with two radiologists was reached, differences in both malignant and presumable nonspecific tracer accumulation were analyzed. RESULTS: Differences in terms of miTNM stages in both studies occurred in nine of the 46 patients (19.6%). The miT stages differed in five patients (10.9%), the miN stages differed in three patients (6.5%), and different miM stages occurred only in one patient who was upstaged in [18F]-F-PSMA-1007 PET. Concordant miTNM stages were obtained in 37 patients (80.4%). There was no significant difference between [18F]-F-PSMA-1007 and [68Ga]-Ga-PSMA-11 in the SUVmax locally (31.5 vs. 32.7; p = 0.658), in lymph node metastases (28.9 vs. 24.9; p = 0.30) or in bone metastases (22.9 vs. 27.6; p = 0.286). In [18F]-F-PSMA-1007 PET, more patients featured presumable unspecific uptake in the lymph nodes (52.2% vs. 28.3%; p: < 0.001), bones (71.7% vs. 23.9%; p < 0.001) and ganglia (71.7% vs. 43.5%; p < 0.001). Probable unspecific, exclusively [18F]-F-PSMA-1007-positive lesions mainly occurred in the ribs (58.7%), axillary lymph nodes (39.1%) and cervical ganglia (28.3%). CONCLUSION: In terms of miTNM staging, both tracers appeared widely exchangeable, as no tracer relevantly outperformed the other. The differences between the two tracers were far more common in presumable unspecific lesions than in malignant spots. A routinely performed two-tracer study could not be shown to be superior. Since it seems at least challenging for most nuclear medicine departments to provide both [18F]-F-PSMA-1007 and [68Ga]-Ga-PSMA-11, it appears reasonable to choose the PSMA radiotracer depending on local availability with attention to the greater occurrence of nonspecific bone findings with [18F]-F-PSMA-1007.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Hoberück S, Löck S, Borkowetz A, et al. Intraindividual comparison of [68 Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. EJNMMI Res. 2021. PMID: 34665337. doi:10.1186/s13550-021-00845-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。